# US 2024/0189363 A1 · Cardiomyocytes and compositions and methods for producing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189363 A1
- Document ID: US20240189363A1
- Status: Published application
- Kind: A1
- Application number: 18/508,057
- Filed: 2023-11-13
- Published: 2024-06-13
- Earliest claimed: 2019-06-06
- Assignees: President and Fellows of Harvard College; Children's Medical Center Corporation
- Applicants: President and Fellows of Harvard College; The Children's Medical Center Corporation
- Inventors: Richard T. Lee; Jessica Garbern; Douglas A. Melton; Aharon Helman
- Web page: https://patentgrep.com/patent/US20240189363A1

## CPC

- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 38/005: {Enzyme inhibitors (protease inhibitors A61K38/55)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C12N 5/0657: {Cardiomyocytes; Heart cells}
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/45: from artificially induced pluripotent stem cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are methods for generating mature cardiomyocytes and compositions including mature cardiomyocytes. Also disclosed herein are methods for enhancing maturation of quiescent cardiomyocytes and compositions including mature quiescent cardiomyocytes.

## Claims

### Claim at position 1

-105. (canceled)

### Claim 106

A method of inducing quiescence of a cardiomyocyte comprising contacting a senescent cardiomyocyte with a cardiomyocyte maturation factor, thereby inducing the senescent cardiomyocyte to transition into a quiescent cardiomyocyte, wherein the quiescent cardiomyocyte is a mature cardiomyocyte and wherein the mature cardiomyocyte exhibits increased expression of REST and/or GATA4 as compared to an immature cardiomyocyte.

### Claim 107 (depends on 106)

The method of claim 106, wherein the cardiomyocyte maturation factor is an upregualtor of p53 and/or an mTOR inhibitor.

### Claim 108 (depends on 106)

The method of claim 106, wherein the cardiomyocyte maturation factor is Torin1.

### Claim 109 (depends on 106)

The method of claim 106, wherein the cardiomyocyte maturation factor is a combination of Torin1 and nutlin-3a.

### Claim 110 (depends on 106)

The method of claim 106, wherein the cardiomyocyte maturation factor is not Torin1.

### Claim 111 (depends on 106)

The method of claim 106, wherein the quiescent cardiomyocyte exhibits increased expression of one or more quiescence markers.

### Claim 112 (depends on 111)

The method of claim 111, wherein the one or more quiescence markers are selected from the group consisting of p16 and p130.

### Claim 113 (depends on 106)

The method of claim 106, wherein the quiescent cardiomyocyte exhibits decreased expression of one or more proliferative markers.

### Claim 114 (depends on 113)

The method of claim 113, wherein the one or more proliferative markers are selected from the group consisting of Ki67, cyclin C1, and E2F1.

### Claim 115 (depends on 106)

The method of claim 106, wherein the quiescent cardiomyocyte is a mature cardiomyocyte.

### Claim 116 (depends on 115)

The method of claim 115, wherein the mature cardiomyocyte exhibits increased expression of one or more sarcomeric proteins as compared to an immature cardiomyocyte.

### Claim 117 (depends on 116)

The method of claim 116, wherein the one or more sarcomeric proteins are selected from the group consisting of: TNNT2, TNNI3, MYH6, and MYH7.

### Claim 118 (depends on 115)

The method of claim 115, wherein the mature cardiomyocyte exhibits increased expression of one or more ion channel genes as compared to an immature cardiomyocyte.

### Claim 119 (depends on 118)

The method of claim 118, wherein the one or more ion channel genes are selected from the group consisting of: KCNJ2, HCN4, SCN5a, RYR2, CACNA1c, and SERCA2a.

### Claim 120 (depends on 115)

The method of claim 115, wherein the mature cardiomyocyte exhibits increased expression of REST and/or GATA4 as compared to an immature cardiomyocyte.

### Claim 121 (depends on 115)

The method of claim 115, wherein the mature cardiomyocyte exhibits a decreased beating rate as compared to an immature cardiomyocyte.

### Claim 122 (depends on 115)

The method of claim 115, wherein the mature cardiomyocyte is an electrically mature cardiomyocyte, a contractility mature cardiomyocyte and/or a metabolically mature cardiomyocyte.

### Claim 123 (depends on 106)

A method of treatment comprising administering to a subject in need thereof a composition comprising a quiescent cardiomyocyte produced according to the method of claim 106.

### Claim 124 (depends on 123)

The method of claim 123, wherein the subject has, or is at risk of developing, a ventricular arrhythmia, decreased systolic heart function, chronic heart failure, congenital heart disease, or other heart disease.
